Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 402-070-1 | CAS number: 88122-99-0 UVINUL T 150
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No specific toxicokinetic data are available, however it can be predicted that the substance will have low oral and dermal bioavailability. It is expected that the physiochemical parameters will limit the distribution and metabolism of the substance. The majority of orally ingested product is expected to be excreted unchanged in the faeces.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Absorption
The physiochemical parameters, such as molecular weight, water solubility and log P would strongly suggest that majority of any dose would not be absorbed following either oral of dermal exposure. Furthermore, oral sub-chronic and acute testing has shown that there is no overt toxicity produced by dosing with the substance which could suggest that the substance is not well absorbed.
Distribution
As with absorption, physiochemical parameters, such as molecular weight, water solubility and log P would strongly suggest that the majority of any oral dose would not be distributed beyond the site of exposure. With regards to bioaccumulation, the weight of evidence would suggest the Uvasorb ET has a very low BCF potential (1 L/kg; as estimated by the CAESAR structure activity relationship program).
Metabolism
It is difficult to predict metabolism in the absence of empirical data, and any metabolite produced will be in very small quantities (due to the lack of absorption and distribution). As such it is recommended that no further studies be conducted to further investigate this.
Excretion
Excretion following oral administration is expected to be mainly faecal due to the predicted lack of absorption.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
